Methylphenidate is a centrally acting sympathomimetic used for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents and for narcolepsy in adults. Despite the growing use among adult women, no reliable data on the prevalence of use during pregnancy have been published, and safety during pregnancy has not been established. We systematically reviewed available data on birth outcome after human in utero exposure to methylphenidate. Systematic searches in PubMed/Embase were performed from origin to August 2012, and data from Michigan Medicaid recipients, The Collaborative Perinatal Project and the Swedish Birth Registry were evaluated. Excluding three case-reports, a total of 180 children exposed to methylphenidate in utero during first trimester were identified, among whom 4 children with major malformations were observed. Methylphenidate exposure during pregnancy does not appear to be associated with a substantially (i.e. more than two-fold) increased risk of congenital malformations.
Basic and Clinical Pharmacology and Toxicology, 2013, Vol 112, Issue 2, p. 73-76